With a pivotal phase II/III trial to start "in the next several weeks," Oxigene Inc. CEO William Schwieterman told BioWorld Today that the just-published results on CA4P (fosbretabulin) paired with approved cancer therapy Avastin (bevacizumab, Roche AG) in recurrent ovarian cancer "are potentially huge for the field" of vascular-targeted therapy in solid tumors. "While [CA4P] is old, we have a new plan and a new story," he said.